Daiwa Securities Group
CRVS icon

Daiwa Securities Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Daiwa Securities Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-225
Closed -$2K – 1245
2025
Q4 		$2K Sell
225
-175
-44% -$1.38K ﹤0.01% 1300
2025
Q3 		$3K Hold
400
– – ﹤0.01% 1237
2025
Q2 		$2K Hold
400
– – ﹤0.01% 1209
2025
Q1 		$1K Buy
+400
New +$1.88K ﹤0.01% 1220
2018
Q4 		– Sell
-116
Closed -$1K – 1154
2018
Q3 		$1K Hold
116
– – ﹤0.01% 1146
2018
Q2 		$1K Hold
116
– – ﹤0.01% 1163
2018
Q1 		$1K Buy
+116
New +$1.1K ﹤0.01% 1147

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Daiwa Securities Group's CRVS Position: Q1 2026 in Review

Daiwa Securities Group sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 225 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in CRVS in Q1 2018 and held it in 7 quarters. The position peaked at $3K in Q3 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Daiwa Securities Group reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 225 Corvus Pharmaceuticals shares in Q1 2026, an estimated $2K.
  • Daiwa Securities Group first reported a position in Corvus Pharmaceuticals in Q1 2018 and held it in 7 quarters.
  • Daiwa Securities Group's Corvus Pharmaceuticals position peaked at $3K in Q3 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.